All News

RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
bone%20dense.jpg (keep)

Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis

d Jack Cush, MD

The effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate.

Read Article
overdose.narcotic.jpg

Prescription Painkiller Misuse in Chronic Pain Patients

d EurekAlert!

A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.

Read Article
back, LBP, spine, AS

Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients

d Jack Cush, MD

Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).

Read Article
ANCA, vasculitis, test

Relapses with Rituximab Maintenance in ANCA-associated Vasculitis

d Jack Cush, MD

Real-world, retrospective study of microscopic-polyangiitis (ΜPA) and granulomatosis-with-polyangiitis (GPA) patients shows that rituximab (RTX) maintenance was associated with 25% risk of relapse and that lower relapse rates was seen with RTX plus cyclophosphamide treatment.

Read Article
RA,polyarticular,black,rheumatoid

Economic, Personal Burden of RA: Maybe Not So Bad?

d MedPage Today

Data from a major federal survey indicate that people with rheumatoid arthritis (RA) don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.

Read Article
EU study of 1052 systemic sclerosis pts failed to show early immunosuppressive use (vs late) lowered ILD risk. Early Rx (Dz Dur < 3yrs) group (n=547, 52%) more male, diffuse Dz, 60% Rx w/ MTX (1.7% biologics); ILD in 47% after3.6yrs (HR 1.13;0.93–1.38) https://t.co/PtQlgyX0TE https://t.co/R7X3zvPvIg

Links:

Dr. John Cush RheumNow ( View Tweet)
Tick-borne diseases have increased in the last decade in the US, including Lyme disease (~476 000/yr), babesiosis, human granulocytic anaplasmosis (HGA), Rocky Mountain spotted fever, monocytic ehrlichiosis (HME), alpha gal allergy (red meat allergy) https://t.co/tl8qPyjU3Z https://t.co/AP0wglsJXM

Links:

Dr. John Cush RheumNow ( View Tweet)
The adipokine Resistin - predicts disease severity and survival in patients with pulmonary arterial hypertension. High resistin levels (>4.5ng/mL) in PAH assoc w/ older age, shorter 6-min walk, decr CV performance, incr death (HR 2.6) https://t.co/TUR4KnVsR9 https://t.co/rc6IMNWH4w

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective Vasculitis Study of Takayasu’s Arteritis - 236 pts, 92% women, mean age 36 yrs, Dz duration 2.6yrs. Damage present in >80% at baseline (75% vascular, 40+% cardiac), even with recent Dx and >40% pts accrue new, mainly disease-specific damage https://t.co/DKZQdH4HuZ https://t.co/LVjqAZYnOZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Barriers to Treat-to-Target in Rheumatoid Arthritis A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation. https://t.co/CMEd62BfU0 https://t.co/YHQ408No4S

Links:

Dr. John Cush RheumNow ( View Tweet)
Economic, Personal Burden of RA: Maybe Not So Bad? Data from a major federal survey indicate that people with RA don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found. https://t.co/ZFw7KZ0Wsb https://t.co/bO02YbzWvb

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM Clinical Images: Coup de Sabre (linear scleroderma) 70-year-old woman with a history of hypothyroidism presented to the dermatology clinic with a 1-year history of progressive indentation and darkening of the skin of her forehead https://t.co/RiVNQiy5MM https://t.co/pxVEqBIUWP

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM). https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Forecast: 70% Increase by 2050 The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2021 has forecasted prevalence of gout to increase by 70% by 2050. https://t.co/7OSQXSBtUc https://t.co/p9hkO5xzAa

Links:

Dr. John Cush RheumNow ( View Tweet)
PROs: Their Proper Place https://t.co/gYjrRcqLy4 https://t.co/QJ9DYp8JuV

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank 11+ yr study of 5728 incident gout pts - light alcohol decreased in gout incidence among females (HR 0.78). Light red wine also reduced gout risk, whereas beer or cider, champagne or white wine, and spirits increased the gout risk at any dose. https://t.co/nP8vObFsOH https://t.co/DuXQMyeaE3

Links:

Dr. John Cush RheumNow ( View Tweet)
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja

Links:

Dr. John Cush RheumNow ( View Tweet)
Lead with Lupus (8.2.2024) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv - leading with lupus because everyone wants to know about lupus! https://t.co/kzoijNGyfd https://t.co/S2llbb0pMO

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA issued draft guidance, which, if implemented, would remove requirement for a switching study for demonstrating biosimilar interchangeability. Citing research showing no additional safety concerns if pts switched from reference biologics to biosimilars https://t.co/MBvI4yxajW https://t.co/sEE654E2rl

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×